IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

BAREI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 855
NA - Nord America 466
EU - Europa 298
SA - Sud America 105
AF - Africa 27
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.752
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 445
CN - Cina 319
SG - Singapore 304
BR - Brasile 86
IT - Italia 79
DE - Germania 60
HK - Hong Kong 55
VN - Vietnam 48
IN - India 38
RU - Federazione Russa 36
NL - Olanda 25
GB - Regno Unito 20
FR - Francia 18
KR - Corea 18
CI - Costa d'Avorio 17
FI - Finlandia 15
ID - Indonesia 15
JP - Giappone 15
ES - Italia 14
CA - Canada 13
TR - Turchia 12
PL - Polonia 11
AR - Argentina 8
BD - Bangladesh 8
MX - Messico 6
ZA - Sudafrica 6
SE - Svezia 5
AT - Austria 4
CO - Colombia 4
IE - Irlanda 3
IL - Israele 3
PK - Pakistan 3
PT - Portogallo 3
EC - Ecuador 2
IQ - Iraq 2
IR - Iran 2
MA - Marocco 2
NP - Nepal 2
PY - Paraguay 2
UA - Ucraina 2
UZ - Uzbekistan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BH - Bahrain 1
CL - Cile 1
CY - Cipro 1
CZ - Repubblica Ceca 1
HT - Haiti 1
JM - Giamaica 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MW - Malawi 1
PH - Filippine 1
PS - Palestinian Territory 1
SY - Repubblica araba siriana 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 1.752
Salva come PNG Salva come JPEG
Città #
Ashburn 134
Singapore 124
Hefei 118
Dallas 51
Beijing 44
Los Angeles 38
Milan 38
Hong Kong 37
Santa Clara 27
Bengaluru 26
Frankfurt am Main 26
Munich 20
Abidjan 17
Hanoi 16
Denver 14
Ho Chi Minh City 14
Seoul 14
Buffalo 12
Jakarta 12
New York 12
Montreal 10
Tokyo 10
Guangzhou 9
Boardman 8
Chicago 8
Helsinki 8
Warsaw 8
Council Bluffs 7
Moscow 7
Phoenix 7
Shanghai 7
São Paulo 7
Istanbul 6
Manaus 6
Chandler 5
Houston 5
Johannesburg 5
Nuremberg 5
Orem 5
Ankara 4
Chennai 4
City of London 4
Düsseldorf 4
Lappeenranta 4
Shenzhen 4
Bologna 3
Brasília 3
Brooklyn 3
Cangzhou 3
Casoria 3
Congonhas 3
Dublin 3
Freiburg im Breisgau 3
Gravatá do Ibiapina 3
Haiphong 3
Lauterbourg 3
London 3
Manchester 3
Poplar 3
Providence 3
San Francisco 3
Suzhou 3
Turin 3
Turku 3
Yongin-si 3
Amsterdam 2
Belo Horizonte 2
Berlin 2
Boston 2
Campinas 2
Campolongo Maggiore 2
Chongqing 2
Curitiba 2
Da Nang 2
Genoa 2
Grodzisk Mazowiecki 2
Kilburn 2
Lanzhou 2
Lisbon 2
Mumbai 2
New Delhi 2
Nova Iguaçu 2
Nuevo Casas Grandes 2
Oniferi 2
Patna 2
Pistoia 2
Porto Alegre 2
Querétaro 2
Quảng Ngãi 2
Ribeirão das Neves 2
Salt Lake City 2
San Vito al Tagliamento 2
Santo André 2
Seattle 2
Shijiazhuang 2
Silver Spring 2
Solihull 2
Stanfield 2
Tampa 2
Tashkent 2
Totale 1.081
Salva come PNG Salva come JPEG
Nome #
Ulcerative injection site reaction after third COVID-19 vaccine dose with mRNA-1273 121
Omalizumab for the Treatment of Chronic Spontaneous Urticaria in Adults and Adolescents: An Eight-Year Real-Life Experience 117
Does body mass index impact the clinical response to dupilumab therapy in atopic dermatitis? A monocentric study of 170 patients 110
Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors 101
Five cases of new-onset pemphigus following vaccinations against coronavirus disease 2019 96
Long-term efficacy and safety of dupilumab in adolescents with severe atopic dermatitis: a 3-year real-life study 88
Abrupt Bullous Cutaneous Eruption After Application of Tacrolimus Ointment and Sun Exposure 87
Severe Allergic Contact Dermatitis to Hair Dye in a Patient With Atopic Dermatitis During Dupilumab Therapy 78
A case of Grover disease treated with Dupilumab: Just serendipity or a future perspective? 78
Special sites in atopic dermatitis: Effectiveness of dupilumab on the hands in a single‐centre study on 485 patients 77
Three cases of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by proton-pump inhibitors 76
Successful treatment of prurigo nodularis with upadacitinib 74
Reply to “New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin” 74
Efficacy and Drug Survival of Tralokinumab in Severe Atopic Dermatitis: An 18-Month Multicenter Experience 71
Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16-week multicentre retrospective study 61
Three-year observational study on the ​long-term efficacy and safety of dupilumab in elderly patients with severe atopic dermatitis 61
Effectiveness of dupilumab in tralokinumab-resistant patients with atopic dermatitis: A real-world experience from two referral centres 61
Dermoscopic features of dermal duct tumors 60
Effectiveness of dupilumab in atopic dermatitis on the head and neck: a single-center study on 553 patients 59
Tralokinumab as a therapeutic option for patients with concurrent atopic dermatitis and alopecia areata 57
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study 57
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes 55
Dupilumab: a new frontier for chronic urticaria. A case series and review of the literature 53
Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience 35
Effectiveness of Dupilumab and Tralokinumab in Treating Nummular Eczema 13
Therapeutic outcomes across Janus kinase inhibitors in prurigo nodularis 11
Cutaneous angiosarcoma of the head: a case from Italy 10
Five-year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real-world study 9
Totale 1.850
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.063
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.063
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222 0 0 0 0 0 0 0 0 0 0 2 0
2022/202346 0 0 0 8 6 4 1 6 8 3 7 3
2023/202492 1 9 5 7 24 5 7 7 2 7 9 9
2024/2025394 2 31 13 16 26 18 27 21 32 34 41 133
2025/20261.316 236 255 260 293 241 31 0 0 0 0 0 0
Totale 1.850